309 related articles for article (PubMed ID: 28343896)
1. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
[TBL] [Abstract][Full Text] [Related]
2. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
[TBL] [Abstract][Full Text] [Related]
4. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.
Su TS; Yang HM; Zhou Y; Huang Y; Liang P; Cheng T; Chen L; Li LQ; Liang SX
Radiat Oncol; 2019 Mar; 14(1):50. PubMed ID: 30917853
[TBL] [Abstract][Full Text] [Related]
5. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
7. Comparison Between Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Assessing the Prognosis of Hepatocellular Carcinoma After Stereotactic Ablative Radiation Therapy.
Lo CH; Liu MY; Lee MS; Yang JF; Jen YM; Lin CS; Chao HL; Shen PC; Huang WY
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):145-152. PubMed ID: 28816140
[TBL] [Abstract][Full Text] [Related]
8. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation.
Pursley J; El Naqa I; Sanford NN; Noe B; Wo JY; Eyler CE; Hwang M; Brock KK; Yeap BY; Wolfgang JA; Hong TS; Grassberger C
Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):986-995. PubMed ID: 32353390
[TBL] [Abstract][Full Text] [Related]
10. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma.
Wang YY; Zhong JH; Su ZY; Huang JF; Lu SD; Xiang BD; Ma L; Qi LN; Ou BN; Li LQ
Br J Surg; 2016 May; 103(6):725-734. PubMed ID: 27005482
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Velec M; Haddad CR; Craig T; Wang L; Lindsay P; Brierley J; Brade A; Ringash J; Wong R; Kim J; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):939-946. PubMed ID: 28333016
[TBL] [Abstract][Full Text] [Related]
12. The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy.
Jackson WC; Hartman HE; Gharzai LA; Maurino C; Karnak DM; Mendiratta-Lala M; Parikh ND; Mayo CS; Haken RKT; Schipper MJ; Cuneo KC; Lawrence TS
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):127-134. PubMed ID: 33878421
[TBL] [Abstract][Full Text] [Related]
13. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
15. Albumin-bilirubin score is a useful predictor of worsening liver reserve after stereotactic body radiation therapy in elderly Japanese patients with hepatocellular carcinoma.
Yoshino Y; Suzuki G; Shiomi H; Kimoto T; Seri S; Yamazaki H; Yamada K
J Radiat Res; 2024 Mar; 65(2):244-250. PubMed ID: 38415344
[TBL] [Abstract][Full Text] [Related]
16. Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma.
Dreher C; Høyer KI; Fode MM; Habermehl D; Combs SE; Høyer M
Acta Oncol; 2016 Jul; 55(7):886-91. PubMed ID: 26878669
[TBL] [Abstract][Full Text] [Related]
17. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H
Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.
Jun BG; Kim YD; Cheon GJ; Kim ES; Jwa E; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Lee SH; Kim HS
Korean J Intern Med; 2018 Nov; 33(6):1093-1102. PubMed ID: 28844122
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
Son SH; Choi BO; Ryu MR; Kang YN; Jang JS; Bae SH; Yoon SK; Choi IB; Kang KM; Jang HS
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1073-80. PubMed ID: 20207492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
